- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 159-173 of
188 results
1010 Exhibit: US Patent Application Publication No 20060078623 to Dhoot et al
Document
PGR2021-00088, No. 1010-9 Exhibit - US Patent Application Publication No 20060078623 to Dhoot et al (P.T.A.B. May. 28, 2021)
|
|
Cite Document
1031 Exhibit: Kehne Therapeutic Utility of Non Peptidic CRF1 Receptor Antagonists...
Document
PGR2021-00088, No. 1031-30 Exhibit - Kehne Therapeutic Utility of Non Peptidic CRF1 Receptor Antagonists in Anxiety, Depression, and Stress Related Disorders Evidence from Animal Models...
|
|
Cite Document
1002 Exhibit: US Prosecution History of the 908 Patent
Document
PGR2021-00088, No. 1002-2 Exhibit - US Prosecution History of the 908 Patent (P.T.A.B. May. 28, 2021)
|
|
Cite Document
1021 Exhibit: Merke New Ideas for Medical Treatment of Congenital Adrenal Hyper...
Document
PGR2021-00088, No. 1021-20 Exhibit - Merke New Ideas for Medical Treatment of Congenital Adrenal Hyperplasia (P.T.A.B. May. 28, 2021)
|
|
Cite Document
1007 Exhibit: US Patent Application Publication No 20050209250 to Romano
Document
PGR2021-00088, No. 1007-6 Exhibit - US Patent Application Publication No 20050209250 to Romano (P.T.A.B. May. 28, 2021)
|
|
Cite Document
1033 Exhibit: Shargel Applied Biopharmaceutics Pharmacokinetics
Document
PGR2021-00088, No. 1033-32 Exhibit - Shargel Applied Biopharmaceutics Pharmacokinetics (P.T.A.B. May. 28, 2021)
|
|
Cite Document
1022 Exhibit: Merke Future Directions in the Study and Management of Congenital ...
Document
PGR2021-00088, No. 1022-21 Exhibit - Merke Future Directions in the Study and Management of Congenital Adrenal Hyperplasia due to 21 Hydroxylase Deficiency (P.T.A.B. May. 28, 2021)
|
|
Cite Document
1029 Exhibit: Williams, Corticotropin Releasing Factor 1 Receptor Antagonists
Document
PGR2021-00088, No. 1029-28 Exhibit - Williams, Corticotropin Releasing Factor 1 Receptor Antagonists (P.T.A.B. May. 28, 2021)
|
|
Cite Document
1023 Exhibit: Microparticles Formulation as a Targeting Drug Delivery System, J Na...
Document
PGR2021-00088, No. 1023-22 Exhibit - Microparticles Formulation as a Targeting Drug Delivery System, J Nanomed Res (P.T.A.B. May. 28, 2021)
|
|
Cite Document
1032 Exhibit: Goodman Gilmans The Pharmacological Basis of Therapeutics
Document
PGR2021-00088, No. 1032-31 Exhibit - Goodman Gilmans The Pharmacological Basis of Therapeutics (P.T.A.B. May. 28, 2021)
|
|
Cite Document
1020 Exhibit: Gully 4 2 Chloro 4 methoxy 5 methylphenyl N 1S 2 cyclopropyl 1 3 fluo...
Document
PGR2021-00088, No. 1020-19 Exhibit - Gully 4 2 Chloro 4 methoxy 5 methylphenyl N 1S 2 cyclopropyl 1 3 fluoro 4 methylphenylethyl5 methyl N 2 propynyl 1,3 thiazol 2 amine Hydrochloride SSR...
|
|
Cite Document
1028 Exhibit: Neurocrine Biosciences Reports Positive Phase II Data for Crinecerfo...
Document
PGR2021-00088, No. 1028-27 Exhibit - Neurocrine Biosciences Reports Positive Phase II Data for Crinecerfont in Adults with Congenital Adrenal Hyperplasia at ENDO Online 2020, Neurocrine B...
|
|
Cite Document
1013 Exhibit: Speiser et al, Congenital Adrenal Hyperplasia Due to Steroid 21 Hydr...
Document
PGR2021-00088, No. 1013-12 Exhibit - Speiser et al, Congenital Adrenal Hyperplasia Due to Steroid 21 Hydroxylase Deficiency (P.T.A.B. May. 28, 2021)
|
|
Cite Document
1027 Exhibit: Neurocrine Biosciences to Present New Data Analyses for Crinecerfo...
Document
PGR2021-00088, No. 1027-26 Exhibit - Neurocrine Biosciences to Present New Data Analyses for Crinecerfont in Adults with Classical Congenital Adrenal Hyperplasia at ENDO 2021, Neurocrine...
|
|
Cite Document
1030 Exhibit: Zorrilla Progress in Corticotropin Releasing Factor 1 Antagonist Deve...
Document
PGR2021-00088, No. 1030-29 Exhibit - Zorrilla Progress in Corticotropin Releasing Factor 1 Antagonist Development (P.T.A.B. May. 28, 2021)
|
|
Cite Document
